DELHI, India, March 13, 2017 /PRNewswire/ --
Scientists at Invictus Oncology Pvt. Ltd. have utilized a novel linkerchemistry to generate antibody-drug conjugates which act like 'magic bullets', a concept proposed by Nobel laureate, Paul Ehrlich. This technology can provide a targeted therapy to cancer patients whereby the antibody can
About Invictus Oncology Private Limited
Invictus Oncology is a biopharmaceutical company based in Delhi, India focused on the development of novel therapeutics for cancer treatment. Invictus was co-founded by Harvard Medical School's Dr. Shiladitya Sengupta and Padma Vibhushan Dr. Raghunath A. Mashelkar.
Invictus has assembled a world-class management and scientific team, alongside a Board of Directors and Scientific Advisory Board that collectively have a significant track record of conducting acclaimed scientific research, developing breakthrough products and building sustainable businesses. Invictus is backed by Navam Capital, Aarin Capital and Ratan Tata.
Media Contact: Monideepa Roy firstname.lastname@example.org Invictus Oncology Private Limited
SOURCE Invictus Oncology Private Limited
Subscribe to our Free Newsletters!
Black food is the new green owing to its health benefits from cardiovascular health to weight loss. ...
Scurvy is a condition that occurs due to the deficiency of vitamin C. It occurs only rarely, since ...
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...View All